Hoffmann-La Roche Limited (Roche Canada)

Roche Canada is a healthcare company that unites leading science and technology across diagnostics, medicines and digital solutions to prevent, stop and cure diseases. 

We focus on areas including oncology, neurology, cardiovascular and metabolic diseases, ophthalmology, infectious diseases and immunology to provide real and positive change for patients, the people they love, and the professionals who care for them.

Roche was founded in Basel, Switzerland in 1896 and began its journey in Canada in 1931. Today, Roche Canada employs nearly 2,000 people at its offices in Mississauga, Ontario, in Laval, Quebec, and across the country.

For more information, please visit www.RocheCanada.com or follow Roche Canada on LinkedIn.



Contact Information
[email protected]
Making a selection with these dropdown will cause content on this page to change. News listings will update as each option is selected.

Latest

Aug 18, 2026, 10:00 ET Roche Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) successfully complete negotiations for Perjeta® (pertuzumab) for the neoadjuvant treatment of aggressive early stage breast cancer

Hoffmann-La Roche Limited (Roche Canada) is pleased to announce that it successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for Perjeta (pertuzumab for injection) ...

Aug 11, 2026, 10:00 ET Itovebi® (inavolisib) now publicly funded in Quebec for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation following unanimous recognition of therapeutic value by...

Hoffmann-La Roche Limited (Roche Canada) is pleased to share that following unanimous therapeutic value recognition from the Institut national d'excellence en santé et en services sociaux (INESSS)...

Jun 25, 2026, 10:00 ET Gazyva® (obinutuzumab) receives positive reimbursement recommendation from the Institut national d'excellence en santé et en services sociaux (INESSS) for persons with active lupus nephritis

The INESSS recommendation is the latest step towards public access to Gazyva (obinutuzumab) for persons with active lupus nephritis who are receiving standard therapy 1 Provincial jurisdictions will...

Jun 23, 2026, 09:00 ET Roche Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) have successfully completed negotiations for Itovebi® (inavolisib), a targeted treatment for advanced hormone receptor-positive,...

MISSISSAUGA, ON, June 23, 2026 /CNW/ - Hoffmann-La Roche Limited (Roche Canada) is pleased to announce that it successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) ...

Jun 08, 2026, 09:00 ET Health Canada authorizes Lunsumio® (mosunetuzumab) for the treatment of relapsed or refractory follicular lymphoma after two or more systemic therapies

MISSISSAUGA, ON, June 8, 2026 /CNW/ - Hoffmann-La Roche Limited (Roche Canada) is pleased to announce that Health Canada has granted market authorizations for Lunsumio (mosunetuzumab for injection)...

May 22, 2026, 10:00 ET Gazyva® (obinutuzumab) receives positive reimbursement recommendation from Canada's Drug Agency (CDA-AMC) for adults with active lupus nephritis

The CDA-AMC recommendation is the latest step towards public access to Gazyva (obinutuzumab) for adult patients with active lupus nephritis who are receiving standard therapy 1 Provincial...

Feb 24, 2026, 13:00 ET Itovebi® (inavolisib) marks milestone as the first breast cancer treatment funded through Ontario's new faster access program

Ontario's FAST program aims to speed up access to breakthrough cancer drugs for patients by almost a full year sooner.1 Itovebi offers a targeted treatment for advanced HR-positive, HER2-negative...

Jan 26, 2026, 10:00 ET Health Canada authorizes Gazyva® (obinutuzumab) for adults with active lupus nephritis

The approval introduces the first and only anti-CD20 monoclonal antibody shown to improve complete renal response in lupus nephritis, offering a new treatment option for patients and potentially...

Dec 17, 2025, 10:00 ET Health Canada authorizes TNKase® (tenecteplase) for the treatment of Acute Ischemic Stroke (AIS)

The approval marks the first new stroke treatment authorized in nearly 27 years, offering an additional option for managing acute ischemic stroke in Canada. MISSISSAUGA, ON, Dec. 17, 2025 /CNW/ -...

Nov 04, 2025, 09:00 ET VABYSMO® (faricimab injection) Pre-Filled Syringe Now Publicly Funded through Ontario Drug Benefit (ODB) Program

Vabysmo now covered across all three approved indications in the province, giving patients a comprehensively funded option for their needs MISSISSAUGA, ON, Nov. 4, 2025 /CNW/ - Hoffmann-La Roche...

Aug 29, 2025, 09:00 ET VABYSMO® (faricimab injection) Now Publicly Funded for Macular Edema Secondary to Retinal Vein Occlusion (RVO) in Ontario

Vabysmo now covered across all three approved indications in the province, providing patients with a single, comprehensively funded solution MISSISSAUGA, ON, Aug. 29, 2025 /CNW/ - Hoffmann-La Roche...

Aug 21, 2025, 09:00 ET Health Canada Approves Roche's Columvi® (glofitamab) as the First Bispecific Antibody in Canada for Relapsed or Refractory Diffuse Large B-Cell Lymphoma after Initial Therapy

DLBCL is an aggressive cancer with a high risk of progression meaning urgent and effective treatments are needed for people who relapse or have refractory disease This Columvi regimen offers an...

Aug 15, 2025, 09:00 ET VABYSMO® (faricimab injection) Now Publicly Funded For Macular Edema Secondary to Retinal Vein Occlusion (RVO) and Pre-Filled Syringe (PFS) in Quebec

Vabysmo now covered across all three approved indications in the province, providing patients with a comprehensively funded option for their needs MISSISSAUGA, ON, Aug. 15, 2025 /CNW/ - Hoffmann-La...

Jul 22, 2025, 09:00 ET Roche Canada announces Polivy® (polatuzumab vedotin for injection) for the First-Line Treatment of Adults With Large B-Cell Lymphoma is now Publicly Reimbursed in Québec

This marks the first provincial listing of Polivy as a first-line treatment for DLBCL in Canada, highlighting Roche's ongoing commitment to meeting the diverse needs of healthcare systems and...

Jun 11, 2025, 09:00 ET Health Canada Authorizes PiaSky® (crovalimab for injection) As the First Monthly (Every Four Weeks) Subcutaneous Treatment for People With Paroxysmal Nocturnal Hemoglobinuria (PNH)

PiaSky® is the first monthly (every four weeks) subcutaneous treatment for PNH in Canada with the option to self-administer following adequate training(1) PiaSky® (crovalimab for injection) has the...

May 28, 2025, 09:00 ET New study led by Horizon and supported by Roche Canada delivers cancer treatment in the comfort of a patient's home

MISSISSAUGA, ON, May 28, 2025 /CNW/ - For the first time in Canada, a patient has received cancer immunotherapy by subcutaneous (under the skin) injection in their home, thanks to an innovative...

Feb 19, 2025, 09:00 ET Health Canada authorizes Itovebi® (inavolisib film-coated tablets), a targeted treatment for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation

The approval provides another treatment option for breast cancer patients with a PIK3CA mutation, one of the most commonly mutated genes in hormone receptor-positive disease, associated with poor...

Jan 20, 2025, 09:00 ET Health Canada Authorizes Vabysmo® (faricimab injection) Pre-Filled Syringe (PFS) for Three Leading Causes of Vision Loss

Vabysmo PFS is the first and only syringe prefilled with a Health-Canada approved bispecific antibody to treat retinal conditions that can cause blindness1 Designed to simplify administration,...

Dec 13, 2024, 09:00 ET Roche Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) successfully complete negotiations for TECENTRIQ SC (atezolizumab, solution for subcutaneous injection)

MISSISSAUGA, ON, Dec. 13, 2024 /CNW/ - Hoffmann-La Roche Limited (Roche Canada) today announced that it successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for...

Nov 19, 2024, 09:15 ET Roche Canada Announces New Informatics Jobs in Ontario's Life Sciences Sector

These jobs will propel the province towards being a global leader in biomanufacturing and life sciences MISSISSAUGA, ON, Nov. 19, 2024 /CNW/ - Hoffmann-La Roche Limited (Roche Canada) is pleased to...

Oct 09, 2024, 08:00 ET Roche Canada Announces Columvi® (glofitamab for injection) is Publicly Reimbursed in 7 Provinces, Including Quebec, Ontario, Manitoba, Saskatchewan, Nova Scotia, and Newfoundland

Columvi is now publicly covered in 7 provinces, which equates to approximately 74% of the total Canadian population, and is the first and only fixed treatment duration bispecific antibody authorized...

Jul 29, 2024, 09:00 ET Health Canada Authorizes Vabysmo® (faricimab injection) for the Treatment of Macular Edema Secondary to Retinal Vein Occlusion

This is the third indication for Vabysmo®, in addition to neovascular or 'wet' age-related macular degeneration and diabetic macular edema 1 Authorization is based on two phase III studies...

Jul 24, 2024, 08:00 ET Roche Canada and the pan-Canadian Pharmaceutical Alliance (pCPA) successfully complete negotiations for COLUMVI® (glofitamab for injection) for the treatment of Diffuse Large B-cell Lymphoma

MISSISSAUGA, ON, July 24, 2024 /CNW/ - Hoffmann-La Roche Limited (Roche Canada) today announced that it successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for...

Jul 16, 2024, 09:00 ET Health Canada authorizes Alecensaro® (alectinib) as the first and only adjuvant treatment for people with ALK-positive early-stage lung cancer

Alecensaro reduced the risk of disease recurrence or death by 76% in people with ALK-positive resected non-small cell lung cancer, as demonstrated in the Phase III ALINA study1 The approval addresses ...

Jun 06, 2024, 08:00 ET Innovative partnership aims to offer less invasive cancer treatment for New Brunswick patients

SAN DIEGO, June 6, 2024 /CNW/ - Horizon Health Network (Horizon), through an innovative partnership with Roche Canada, the New Brunswick Extra-Mural Program, the Government of New Brunswick and...

Journalists and Bloggers

The news you need, when you need it.

Join PR Newswire for Journalists to access all of the free services designated to make your job easier.

In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.

LEARN MORE
Making a selection with these dropdown will cause content on this page to change. News listings will update as each option is selected.